Is UnitedHealth Still a Good Dividend Stock?

UnitedHealth Group (UNH) shares have fallen 28% this year amid rising costs, missed earnings, a CEO change, and a Department of Justice investigation, leading to an unusually high dividend yield. Despite these headwinds, the company reported $21.3 billion in trailing twelve-month profit and maintains a healthy 37% dividend payout ratio, having recently increased its quarterly dividend by over 5% to $2.21. While its medical care ratio rose to 89.4% due to increased utilization, UNH's strong financials and commitment to dividend growth suggest its payout remains secure, potentially making it an attractive long-term investment at its current valuation.

Analysis

UnitedHealth Group (UNH) shares have experienced a significant 28% decline in 2025, driven by rising expenses, a notable miss on July earnings expectations, a CEO change, and a Department of Justice investigation into billing practices. This confluence of negative factors has led to an unusually high dividend yield, reflecting investor concern over recent operational headwinds.

The increase in expenses is partly attributed to a rise in post-pandemic utilization rates, pushing the medical care ratio to 89.4% from 82.5% in 2019. Despite these pressures, UnitedHealth reported a robust $21.3 billion in trailing 12-month profit and maintains a healthy 37% dividend payout ratio, indicating strong underlying financial capacity.

UnitedHealth recently increased its quarterly dividend by over 5% to $2.21, underscoring management's commitment to shareholder returns. With a current dividend yield of 2.5%, significantly above the S&P 500 average of 1.2%, and a modest price-to-earnings multiple of 15, the stock presents a potentially attractive valuation for long-term income investors. The company's focus on cost trimming is expected to mitigate future MCR increases.

Key Decisions for Investors

• Investors should evaluate UnitedHealth Group (UNH) as a potential long-term buy-on-weakness opportunity, given its current 2.5% dividend yield and modest P/E of 15, which offers a margin of safety.
• Monitor the company's progress in cost-trimming initiatives and the trajectory of its medical care ratio, as these are critical to mitigating expense pressures and sustaining profitability.
• While acknowledging the ongoing Department of Justice investigation and CEO transition as potential short-term risks, the company's strong $21.3 billion trailing profit and 37% payout ratio suggest dividend reliability for income-focused portfolios.